CROI 2023 – progress on efforts to cure HIV
Aelix and Gilead, Immunocore and Corvus are all taking different approaches in the early hunt for a functional cure.
Asco-GU – Talzenna remains a wait-and-see story in prostate cancer
Talapro-2 data backing Talzenna in all-comers are slated by Asco-GU’s discussant, as Lynparza shows precisely what might go wrong.
Asco-GU – Bicycle tries to put distance between itself and Seagen
However, results with BT8009, one of several datasets being presented this week at the Asco-GU conference, fail to convince many investors.
Asco-GI 2023 – zolbetuximab sheds light on Claudin18.2 expression
39% of the patients assessed carried this biomarker, the conference presentation reveals.
Asco-GI 2023 – zolbetuximab opens up a stomach cancer niche
Clinical data back Claudin18.2 as a target for treating stomach cancer – but biomarker diagnosis is needed.
JP Morgan 2023 – Sutro makes its pitch to beat Immunogen
The group reckons it can target twice as many ovarian cancer patients, but an important disclosure shows that its case it not clear-cut.
JP Morgan 2023 – day one sees buyers make the most of straitened times
Takeouts of Cincor, Albireo and Amryt emerge with contingent payment terms, as biopharma buyers flex their muscles.
